Aleve Sinus & Headache NDA
This article was originally published in The Tan Sheet
Labeling supplement (NDA 21-076/S7) for naproxen sodium 220 mg/extended-release pseudoephedrine 120 mg combination approved by FDA July 31. Bayer says agency asked it to file formal supplement to add the Sinus & Headache sub-brand under previously approved NDA for Aleve Cold & Sinus; both products contain the same formulation. Sinus & Headache began shipping in July 2001 (1"The Tan Sheet" July 9, 2001, p. 3)...
You may also be interested in...
Alka-Seltzer Morning Relief will be the first OTC product "specifically indicated to relieve morning headache and fatigue associated with a hangover," Bayer Consumer Care claimed.
Pain relief product sales grew 27% and upper respiratory sales 35% for the week ended 7 March as consumers respond to COVID-19, according to Nielsen data noted in a Jefferies report on consumer health purchasing trends. Private label market share is up slightly, while OTC purchases continue primarily in conventional stores.
Managing partner Corey Goodman said venBio didn’t have trouble closing its fund, because the venture capital firm prepared its investors for an economic downturn months ago.